BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 10401019)

  • 1. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B; Decramer S; Vitkevic R; Wannous H; Bandin F; Azema C; Callard P; Brocheriou I; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
    Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
    Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K; Vincenti F; Filo RS
    Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
    Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
    Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
    Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
    Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events.
    Cantarovich D; Renou M; Megnigbeto A; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Karam G; Soulillou JP
    Transplantation; 2005 Jan; 79(1):72-8. PubMed ID: 15714172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclosporin A and tacrolimus on sister chromatid exchange frequency in renal transplant patients.
    Oztürk S; Ayna TK; Cefle K; Palanduz S; Ciftçi HS; Kaya SA; Diler AS; Türkmen A; Gürtekin M; Sever MS; Carin M
    Genet Test; 2008 Sep; 12(3):427-30. PubMed ID: 18752452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.
    Neuhaus P; Blumhardt G; Bechstein WO; Platz KP; Jonas S; Mueller AR; Langrehr JM; Lohmann R; Schattenfroh N; Knoop M
    Transplantation; 1995 Jan; 59(1):31-40. PubMed ID: 7530868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants.
    Raofi V; Holman DM; Coady N; Vazquez E; Dunn TB; Bartholomew AM; Pollak R; Benedetti E
    Am J Surg; 1999 Apr; 177(4):299-302. PubMed ID: 10326847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus in transplant rejection.
    Rath T
    Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.